Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Multiple Myeloma × Dasatinib × Clear all

Phase

Phase 1 5 Phase 2 2 Phase EARLY_PHASE1 1 Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Leukemia, Myeloid, Chronic-Phase 2 Myeloproliferative Disorders 1 Multiple Myeloma 1 Hematologic Neoplasms 1 Blast Crisis 1

Interventions

Lenalidomide 9 Dexamethasone 9 Zoledronic Acid 7 Bortezomib 7 Melphalan 4 ixazomib 3 daratumumab 3 tocilizumab 2 pomalidomide 2 carfilzomib 2 Prednisone 2 Filgrastim 2 Cyclophosphamide 2 Calcium Dobesilate 2 zanubrutinib 1 talquetamab 1 pegylated granulocyte colony-stimulating factor 1 montelukast 1 isatuximab 1 ibrutinib 1 exifone 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 auricularum 1 apixaban 1 Vaccination 1 Thiotepa 1 Thalidomide 1 Tablets 1 Standard of Care 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05944783 2025-02-12

BE-Dasatinib

Centro de Atencion e Investigacion Medica

Phase 4 Not yet recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡